A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment.
OBJECTIVE
This study compared side effects and patient convenience of vaginal progesterone suppositories (Cyclogest) and vaginal progesterone tablets (Endometrin) used for luteal phase support in in vitro fertilization/embryo transfer (IVF/ET) cycles using pituitary downregulation.


METHODS
One hundred and thirty-two infertile patients were randomized on the day of ET by a computer-generated randomization list in sealed envelopes to receive either Cyclogest 400mg or Endometrin 100mg twice daily for 14 days. On days 6 and 16 after ET, they rated side effects and patient convenience into four grades: none, mild, moderate and severe by completing a questionnaire.


RESULTS
No significant differences in perineal irritation were found on days 6 and 16 after ET between the two groups, although there was a trend of fewer patients with perineal irritation in the Endometrin group. Significantly more patients in the Endometrin group had difficulty of administration on day 6 after ET. There were no differences in the hormonal profile on day 6 after ET and IVF outcomes between the two groups.


CONCLUSIONS
There was no difference in perineal irritation after the use of Cyclogest suppositories or Endometrin tablets for luteal phase support although more patients found administration of Endometrin tablets difficult.
Ng
Ernest Hung Yu
EH
Department of Obstetrics and Gynaecology, The University of Hong Kong, 6/F, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong Special Administrative Region, People's Republic of China. nghye@hkucc.hku.hk
Chan
Carina Chi Wai
CC
Tang
Oi Shan
OS
Ho
Pak Chung
PC
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy / Q000503:physiopathology; D008183:Luteal Phase / Q000187:drug effects*; D010902:Pituitary Gland / Q000187:drug effects / Q000503:physiopathology; D011374:Progesterone / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D013488:Suppositories / Q000009:adverse effects; D013997:Time Factors; D014622:Vaginal Creams, Foams, and Jellies / Q000009:adverse effects
D013488:Suppositories; D014622:Vaginal Creams, Foams, and Jellies; D011374:Progesterone; D004958:Estradiol